Wegovy and Mounjaro treatments are recommended for adults with an initial BMI of 30 kg/m² or higher (classed as living with obesity). They are also appropriate for people with a BMI between 27 kg/m² and 30 kg/m² (classed as overweight) if you also have weight-related health issues such as prediabetes, high blood pressure, sleep apnea, high cholesterol, or heart problems.
Weightloss drugs such as Wegovy and Mounjaro should only be used to help with weight loss if you have already tried and failed to lose weight through exercise and diet alone. GLP-1 drugs include Saxenda, Wegovy, Mounjaro and Ozempic.
These GLP-1 drugs can be used for patients who have a BMI of over 30, or in patients with a BMI over 27, and other risk factors such as;
- Diabetes type 2
- High cholesterol
- Obstructive sleep apnoea
- High blood pressure
Some ethnicities may also change the thresholds for treatment being suitable.
Additionally, if an individual is transferring their treatment from another provider and has documented evidence of successful previous use of these medications, a lower BMI threshold may be accepted. This consideration is determined on a case-by-case basis.